Takeaway
Lysophosphatidic acid (LPA) levels in cerebrospinal fluid (CSF) correlate with pain intensity and symptoms in people with neuropathic pain.
Why this matters
LPA signalling pathways may present a novel target for therapeutic agents in neuropathic pain.